Roivant Sciences Announces Investor Conference for Brepocitinib in Dermatomyositis Treatment

Roivant Sciences and Priovant Therapeutics will host a live investor video conference on June 17, 2025, to discuss brepocitinib, a treatment for dermatomyositis. Brepocitinib, a dual selective inhibitor of TYK2 and JAK1, has shown positive results in seven Phase 2 studies and is currently in Phase 3 trials. The conference aims to highlight its potential impact on patient outcomes, but success is contingent on ongoing clinical trial outcomes.

June 11, 2025

Roivant Sciences (Nasdaq: ROIV) and Priovant Therapeutics will host a live investor video conference on Tuesday, June 17, 2025, at 1:00 PM ET to discuss brepocitinib, a treatment for dermatomyositis (DM). The conference aims to highlight the potential impact of brepocitinib on patient outcomes, but success is contingent on ongoing clinical trial results.

Brepocitinib is a dual selective inhibitor of TYK2 and JAK1, designed to suppress key cytokines linked to autoimmunity. It has shown positive results in seven Phase 2 studies and is currently in Phase 3 trials for DM. The drug is administered as a once-daily oral therapy and has been dosed in over 1,400 subjects [1].

The video conference will provide an opportunity for investors to learn more about brepocitinib's clinical and therapeutic potential, as well as its commercialization prospects. The event will feature presentations and discussions from Roivant and Priovant executives, who will share their insights and expectations regarding the drug's development and future market opportunities.

The conference will be accessible via a registration link provided on Roivant's investor website [2]. An archived webcast will be available after the live event.

References:
[1] https://investor.roivant.com/news-releases/news-release-details/roivant-and-priovant-host-investor-video-conference-100-pm-et
[2] https://www.globenewswire.com/news-release/2025/06/09/3096179/0/en/Roivant-and-Priovant-to-Host-Investor-Video-Conference-at-1-00-PM-ET-on-Tuesday-June-17-on-Brepocitinib-and-the-Unmet-Medical-Need-in-Dermatomyositis.html